Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred ...

Optum Rx officials said they now have eliminated reauthorization requirements for more than 140 chronic disease medications.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...

Corner Therapeutics, an immunotherapy company pioneering novel approaches to cancer and infection, today announced that its Distinguished Scientist, Scientific Co-founder and Board Member, Professor ...

In 2023, there were an estimated 44 thousand total incident cases of kidney transplants across the 7MM, with the number ...

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of ...

TD Cowen analyst Tyler Van Buren initiated coverage of Soleno Therapeutics (SLNO) with a Buy rating and $110 price target The firm says Vykat XR ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

The conference represents a unique collaboration between the Prader-Willi Syndrome Association | USA (PWSA | USA), the Foundation for Prader-Willi Research (FPWR), and the International Prader-Willi ...